Lilly xanomeline 75 mg t.i.d. for Alzheimer's shows efficacy in Phase II, California Clinical Trials official says.
Executive Summary
LILLY XANOMELINE 75 MG T.I.D. FOR ALZHEIMER's SHOWS EFFICACY IN PHASE II, according to California Clinical Trials researcher Neal Cutler, MD. Cutler spoke June 26 at the Drug Information Association annual meeting in Orlando. A 373-patient double-blind placebo-controlled study of Alzheimer's patients found that of three doses tested -- 25, 50, and 75 mg t.i.d. -- the 75 mg dose showed efficacy measured by the ADAS-CoG scale and nurse observation.